US 11,926,675 B2
Antibodies binding CD24, preparation and use thereof
Wenzhi Tian, Shanghai (CN); Song Li, Shanghai (CN); Dianze Chen, Shanghai (CN); and Huiqin Guo, Shanghai (CN)
Assigned to IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC., Shanghai (CN)
Filed by ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Shanghai (CN)
Filed on Mar. 3, 2022, as Appl. No. 17/685,530.
Claims priority of application No. 202111195246.5 (CN), filed on Oct. 13, 2021.
Prior Publication US 2023/0110607 A1, Apr. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2896 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01)] 14 Claims
OG exemplary drawing
 
1. An isolated monoclonal antibody or an antigen binding portion thereof, that binds CD24, comprising
i) a heavy chain variable region, wherein the heavy chain variable region comprises a heavy chain variable region CDR-1 (HV-CDR1), a HV-CDR2, and a HV-CDR3 comprising the amino acid sequences set forth in SEQ ID NOs: 1, 2, and 3, respectively; and
ii) a light chain variable region, wherein the light chain variable region comprises a light chain variable region (CDR-1) (LV-CDR1), a LV-CDR2, and a LV-CDR3 comprising the amino acid sequences set forth in SEQ ID NOs: 4, 5, and 6, respectively.